Navigation Links
Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine

DEERFIELD, Ill., March 29, 2007 /PRNewswire-FirstCall/ -- Baxter International Inc. today announced final Phase I/II data for its adjuvant-free investigational pandemic H5N1 influenza vaccine and plans to initiate a Phase III clinical trial of the candidate vaccine in Europe to confirm the study results.

The Phase I/II study indicated that Baxter's H5N1 candidate vaccine is highly immunogenic at low doses, and induces substantial levels of cross immunity against widely divergent H5N1 strains. The open-label, multi-center Phase III trial is designed to evaluate the safety and efficacy of Baxter's adjuvant-free, whole-virus candidate vaccine. Vaccinations will begin in the first half of this year and results of the Phase III trial are scheduled to be available by the end of 2007.

"The results of the Phase I/II clinical trial suggested that this candidate vaccine may provide protection against divergent strains of virus, even at low dose levels without an adjuvant," said John Oxford, professor of Virology, The Queen Mary School of Medicine, London, United Kingdom. "The Phase III clinical trial is designed to confirm these findings and provide a solid measure of the vaccine's potential to protect a large number of people before and during a possible pandemic."

Baxter's candidate H5N1 vaccine is derived from H5N1 strain A/Vietnam/1203/2004. Its antigen composition and structure closely resembles the actual pathogen circulating in nature. The candidate vaccine induces an immune response (both cell and antibody mediated) that is similar to the body's defense against a natural virus, without the need to incorporate additional agents (adjuvants) to enhance immune response. It is manufactured using the company's proprietary vero cell technology, which produces high- yield vaccine more quickly than traditional approaches because it is not produced in eggs. Baxter's candidate vaccine is the first cell-
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... Oct. 17, 2014 UBM Medica US announces that ... online community and information resource for neurologists and other healthcare ... Alzheimer disease , with discussions of the latest developments ... million Americans have Parkinson disease , more than the total ... Lou Gehrig disease. Diagnosis can be difficult because there ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... MINNEAPOLIS, Oct. 29 The Minnesota State High School ... have teamed up to make the Minnesota State High School tournaments ... MSHSL has purchased eight mobile Automated External Defibrillators (AED) from HeartSine ... Cardiac Arrest (SCA), which is the leading cause of death in ...
... This holiday season, settle your stomach, relieve your wallet ... holidays, when many of us may suffer from occasional heartburn, a ... finds that you probably don,t need an expensive drug like Nexium, ... uses comparative effectiveness research to identify "Best Buys" based on safety, ...
Cached Medicine Technology:Minnesota High School Tournament Sidelines to be More Secure From Sudden Cardiac Arrest 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... SUNDAY, Oct. 19, 2014 (HealthDay News) -- New stem ... eventually lead to new treatments, a new study suggests. ... functioning human intestinal tissue in a lab dish. They ... model for studying intestinal disorders, according to the researchers. ... many diseases and conditions that can cause intestinal failure, ...
(Date:10/19/2014)... Nearly 9,000 transvaginal mesh lawsuits ( ... Johnson’s Ethicon unit have now been centralized in New ... are continuing to move forward, Bernstein Liebhard LLP reports. ... over products part of Ethicon Inc.’s line of Gynecare ... 11th, 2014, which showed an additional 1,600 claims now ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 4
... 16 (HealthDay News) -- Women with rheumatoid arthritis or ... hoped for, according to a new study. These ... cause fertility problems and miscarriage, researchers said. Lupus ... and organs. Rheumatoid arthritis leads to painful joint inflammation. ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... of blood clots in people undergoing certain cancer treatments, ... treated with chemotherapy, they have an increased risk of ... dangerous, and have the potential to cause heart attacks ...
... Denise Mann HealthDay Reporter , WEDNESDAY, Feb. ... also help problem drinkers cut their alcohol consumption, a ... drug curbs drinking is not fully understood, but its ... of sadness and nausea, thereby blunting the pleasurable effects ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... require driver,s education before getting a license, about one-third ... half fail to undergo any formal behind-the-wheel training. ... records were especially unlikely to have received driver,s ed ...
... 15, 2012 California reported the largest decline in drunk-driving ... to recent statistics, and a $232,000 grant from the California ... Safety Administration to UC Irvine,s Health Education Center is ... with the RADD College DUI Awareness Program, UCI has organized ...
... -- Takemi Tanaka, Ph.D., of Thomas Jefferson University,s School ... , received a $50,000 grant toward her breast cancer research, ... for Breast and Cervical Cancer Research" initiative. The ... who choose to contribute all or part of their state ...
Cached Medicine News:Health News:Lupus, Rheumatoid Arthritis Linked to Fertility Woes, Miscarriage 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 3Health News:Stop-Smoking Drug May Also Curb Problem Drinking 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 3Health News:UCI leads multicampus collaboration to reward use of designated drivers 2Health News:Taxpayers give back for cancer: Jefferson researcher awarded 'Refunds for Research' grant 2
... This functional brace is designed for the ... and fibula. The preformed design provides post ... removal of internal or external fixation. The ... and below the fracture site, increasing vascularity ...
... Brace features a multi-axial hinge that duplicates ... altering kinematics. The infinite degree of adjustment ... and extension control of the knee. , ... tibia in correct anatomical alignment. The precision ...
... is a revolutionary cast replacement system for ... leg and foot. , ,A self-adjusting ... and in conjunction with a rigid lattice ... time of fracture or rupture healing can ...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
Medicine Products: